We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

By LabMedica International staff writers
Posted on 22 Oct 2025

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford Nanopore Technologies platforms and extend the collaboration through 2032.

Building upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025, the enhanced collaboration streamlines coordination on the development and commercialization of a broader portfolio of targeted enrichment sequencing kits for the screening and diagnosis of heritable genetic disorders.


Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

"This expanded agreement underscores our commitment to advancing genetic testing solutions that simplify workflows and deliver richer insights for laboratories worldwide," said Matt McManus, President of the Diagnostics and Spatial Biology Segment of Bio-Techne. "By deepening our collaboration with Oxford Nanopore, we are accelerating innovation in diagnostics and creating a foundation for future portfolios."

"We're pleased to expand our collaboration with Bio-Techne to bring new genetic testing solutions to laboratories worldwide. By combining Bio-Techne's diagnostics expertise and innovations with our advanced molecular sensing platform, together we can make testing faster, simpler, and more accessible," added Rosemary Dokos, Chief Product and Marketing Officer of Oxford Nanopore Technologies.

Related Links:
Bio-Techne Corporation 
Oxford Nanopore Technologies


New
Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
New
Rapid Sepsis Test
SeptiCyte RAPID

Latest Industry News

Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
22 Oct 2025  |   Industry

FDA Clears Blood-Based Companion Diagnostic for Advanced Breast Cancer Therapy
22 Oct 2025  |   Industry

CareDx Expands Precision Oncology Portfolio with Naveris Acquisition
22 Oct 2025  |   Industry



ADLM